Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Purpose: This Phase 3, multicenter study (NCT03434041) was conducted in primarily Chinese patients with treatment-resistant depression (TRD) to support the registration of esketamine nasal spray in China. Patients and Methods: This randomized, double-blind, active-controlled study was conducted in China and the United States (US) in patients with TRD (single or recurrent episode). Eligible patients were randomized 1:1 to receive intranasal esketamine or matching placebo, each in conjunction with a newly initiated oral antidepressant (AD; duloxetine, escitalopram, sertraline, and venlafaxine extended release) (ie, esketamine plus AD or AD plus placebo). The primary endpoint, change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 28, was analyzed using a mixed-effects model for repeated measures. Secondary endpoints including safety were also evaluated. Results: Of 252 randomized patients (China, 224; US, 28), 214 completed the double-blind treatment phase. The difference between treatment groups at Day 28 was not statistically significant (difference in least-square means [95% CI]: -2.0 [-4.64, 0.55]; 2-sided p = 0.123). However, esketamine plus AD demonstrated a clinically meaningful treatment difference compared with AD plus placebo in MADRS total score at 24 hours after first dose for the study overall population and China sub-population (difference in least-square mean [95% CI]: -3.3 [-5.33, -1.33] and -2.6 [-4.64, -0.60], respectively). No new safety signals were observed. Conclusion: Esketamine plus AD was not statistically superior to AD plus placebo in improving depressive symptoms in TRD patients at Day 28. Rapid reduction in depressive symptoms within 24 hours was observed for TRD patients treated with esketamine plus AD in the overall population and China sub-population. Safety was consistent with the established safety profile of esketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Of the 3 remaining initiation trials, we confirmed the negative conclusions of NCT02918318 [41] and NCT03434041 [42].”
The cited source says what the claim attributes to it.
In the citing paper
“Our findings are concordant with the direction and general magnitude of effect reported in pivotal trials of adjunctive intranasal esketamine in TRD and the relapse-prevention study (18–23)”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795 · cited 1×
“Efficacy Assessments Efficacy assessments included (1) MADRS, a clinician-rated measure of depression severity,(16) and scored by independent, remote (by phone), blinded MADRS raters to ensure an unbiased efficacy evaluation; (2) Sheehan Disability Scale (SDS), a patient-reported measure of functional impairment and a…”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“During this period, patients continue to experience symptoms and to be at risk of self-harm.(7,11) Therefore, there is an unmet need for TRD intervention and novel treatments for the rapid relief of depressive symptoms.”
BackgroundPrevalence of mental disorders in China: a cross-sectional epidemiological study
Huang, Y., Wang, Y., Wang, H., Liu, Z., Yu, X., Yan, J., Yu, Y., Kou, C., Xu, X., Lu, J., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30511-x · Cited by 2,335 · cited 1×
“4% (approximately 50 million persons).(3) A subset of MDD patients experience treatment-resistant depression (TRD), defined as lack of clinically meaningful improvement after treatment with at least 2 different antidepressants (ADs) at adequate dosage and duration in the current depressive episode.”
BackgroundSynaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651 · cited 1×
“Therefore, there is an unmet need for TRD intervention and novel treatments for the rapid relief of depressive symptoms.(12,13) Esketamine nasal spray (SPRAVATO), the rapidly acting S-enantiomer of ketamine, is approved in conjunction with an oral AD for the treatment of adults with TRD in the United States (US) and t…”
BackgroundSheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
Posner, K., Oquendo, M. A., Gould, M., Stanley, B., & Davies, M. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1035 · Cited by 1,025
Assessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904 · cited 4×
“There were no obvious factors identified to explain the difference in the primary efficacy outcome between China and US subgroups, and global phase 3 TRD studies.(17,33) With respect to PK, esketamine concentrations exhibited the expected dose-dependent differences between the 56 mg and 84 mg doses and were similar to…”
BackgroundResultInfluentialSelf-citationBremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Fedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606 · cited 3×
“There were no obvious factors identified to explain the difference in the primary efficacy outcome between China and US subgroups, and global phase 3 TRD studies.(17,33) With respect to PK, esketamine concentrations exhibited the expected dose-dependent differences between the 56 mg and 84 mg doses and were similar to…”
ResultSelf-citationIonescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Self-citationFu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m13191 · Cited by 376
Self-citationSaveanu, R., Etkin, A., Duchemin, A.-M., Goldstein-Piekarski, A., Gyurak, A., Debattista, C., Schatzberg, A. F., Sood, S., Day, C. V. A., Palmer, D. M., et al. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.12.018 · Cited by 151 · cited 1×
“During this period, patients continue to experience symptoms and to be at risk of self-harm.(7,11) Therefore, there is an unmet need for TRD intervention and novel treatments for the rapid relief of depressive symptoms.”
BackgroundMontgomery, S. A., & Möller, H.-J. (2009) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32832a8eb2 · Cited by 121 · cited 1×
“The average 2-point difference from placebo at endpoint in short-term studies has been used to establish the clinical relevance of an AD against placebo.(28,29) Although the first key secondary endpoint could not be formally evaluated due to the prespecified testing hierarchy, esketamine-treated patients experienced c…”
MethodMelander, H., Salmonson, T., Abadie, E., & van Zwieten-Boot, B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.003 · Cited by 117 · cited 1×
“The average 2-point difference from placebo at endpoint in short-term studies has been used to establish the clinical relevance of an AD against placebo.(28,29) Although the first key secondary endpoint could not be formally evaluated due to the prespecified testing hierarchy, esketamine-treated patients experienced c…”
MethodThe promise of ketamine for treatment‐resistant depression: current evidence and future directions
DeWilde, K. E., Levitch, C. F., Murrough, J. W., Mathew, S. J., & Iosifescu, D. V. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12646 · Cited by 89 · cited 1×
“Therefore, there is an unmet need for TRD intervention and novel treatments for the rapid relief of depressive symptoms.(12,13) Esketamine nasal spray (SPRAVATO), the rapidly acting S-enantiomer of ketamine, is approved in conjunction with an oral AD for the treatment of adults with TRD in the United States (US) and t…”
BackgroundMorbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
Physician Withdrawal Checklist (PWC-20)
Rickels, K., Garcia-Espana, F., Mandos, L. A., & Case, G. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31817efbac · Cited by 59 · cited 1×
“Other safety evaluations included the Columbia-Suicide Severity Rating Scale (C-SSRS) to assess potential suicidal ideation and behavior,(24) the Clinician-Administered Dissociative States Scale (CADSS) to assess dissociative symptoms,(25) and the 20-Item Physician Withdrawal Checklist (PWC-20) to assess potential wit…”
MethodEpidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan
Fife, D., Feng, Y., Wang, M. Y.-H., Chang, C.-J., Liu, C.-Y., Juang, H.-T., Furnback, W., Singh, J., & Wang, B. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.03.006 · Cited by 55
Oral ketamine as a positive control in human abuse potential studies
Shram, M. J., Sellers, E. M., & Romach, M. K. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.10.002 · Cited by 24
Targum, S. D., Daly, E., Fedgchin, M., Cooper, K., & Singh, J. B. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.017 · Cited by 24 · cited 1×
“However, this finding was not observed in another similar pilot study in a US population, which demonstrated that remote blinded ratings were comparable to site-based ratings in this US population with TRD at all timepoints.(35) This may be partly due to cultural and ethnic differences in a Western versus Chinese popu…”
ResultJohnson, K. M., Devine, J. M., Ho, K. F., Howard, K. A., Saretsky, T. L., & Jamieson, C. A. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10253 · Cited by 19
Wang, H., Wu, T., Dong, S., Guan, M., Liu, A., Jiang, K., Chi, R., Qiu, H. X., Dong, W., & Si, T. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.054 · Cited by 9
Research works printed but not linked: 3
- 2018, Definition of Treatment-Resistant Depression in the Medicare Population [Internet]
- 1976, Clinical Global Impressions, In: ECDEU Assessment Manual for Psychopharmacology
- Wang G, Si T, Xu X, et al. Independent telephone-based assessment of depressive symptoms in China. Presented at The International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference, Marina Del Ray, CA. 2018.
Cited by
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 108
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Seshadri, A., Prokop, L. J., & Singh, B. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.03.137 · Cited by 61
New and emerging treatments for major depressive disorder
Njenga, C., Ramanuj, P., de Magalhães, F. J. C., & Pincus, H. A. (2024) · BMJ · doi:10.1136/bmj-2022-073823 · Cited by 59
Metadata
- Authors
- Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J.
- Affiliations
- Capital Medical University (CN)
- Corresponding author
- Wang, Gang
- Fu, Dong-Jing
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2023-03
- Volume
- Volume 19
- Pages
- 693-707
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC10072270
- OpenAlex
- W4362519238
- Cited by
- 35
- References
- 28
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 12 · 2023: 5
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Keywords
- esketamine, nasal spray, treatment-resistant depression, flexible dosing, oral antidepressant, duloxetine, escitalopram, sertraline, venlafaxine extended release, rapid-acting antidepressants, depressive symptom reduction, drug safety, Chinese patients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

